This suggests that passive immunization with tau antibodies is really a viable therapeutic target and that the CSF degree of p-tau262/356 or on the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to monitor tau therapeutics in medical trials.In spite of these promising innovations, you will discover issues to deal w